Effects of imatinib mesylate in patients with polycythemia vera: results of a phase II study
- 265 Downloads
The antiproliferative effects of the tyrosine kinase inhibitor imatinib mesylate were reported in single cases with polycythemia vera (PV). We, therefore, conducted a clinical phase II study to assess the rate and quality of response in patients with PV. Thirty-one patients, with a median age of 64 years (range, 45–84 years), were included. All but one patient were on phlebotomy; 14 (45 %) had previously received cytoreductive therapy. Imatinib was started with 400 mg/day. In 26 % of patients, dose escalation up to 800 mg was performed. After a median treatment duration of 8.3 months (range, 0.1–62.1 months), the overall response rate was 55 %. No complete remission (normalization of all parameters: hematocrit, white blood cell (WBC) count, platelet count, and spleen size determined by ultrasound examination) was reached because the spleen remained enlarged in all patients. Thirteen patients (42 %) achieved partial remission (≥25 % reduction of at least one of the previously mentioned parameters); in 10 of these, the respective reduction was ≥50 %. In four patients (13 %) with minor response, the reduction was <25 %. No change or progressive disease was seen in 14 patients (45 %). The nonresponders had a longer previous disease duration and had received more antecedent cytoreductive therapy (p = 0.009). Compared to baseline characteristics, imatinib induced the reduction of phlebotomies (p = 0.003), of WBC count (p = 0.002), and of platelet count (p = 0.04). Three patients became free from phlebotomies. In six investigated patients, no significant reduction of the JAK2V617F burden was observed despite clinical improvement. The results show that imatinib has moderate cytoreductive effects in PV.
KeywordsPolycythemia vera Imatinib mesylate Treatment effects
The following institutions participated in the study: Allgemeines Krankenhaus St. Georg, Hamburg, Germany (N. Schmitz); Onkologische Schwerpunktpraxis, Augsburg, Germany (O. Brudler, B. Heinrich, and M. Bangerter); Onkologische Schwerpunktpraxis, Jena, Germany (S. Hahnfeld); Universitätsklinik Ulm, Ulm, Germany (M. Griesshammer); Medizinische Universitätsklinik Freiburg, Freiburg im Breisgau, Germany (C. Waller); Medizinische Klinik I, Universitätsklinikum Köln, Cologne, Germany (M. Hallek); Onkologische Schwerpunktpraxis, Leer-Emden, Germany (L. Müller); Universitätsmedizin Mannheim, Mannheim, Germany (E. Lengfelder and K Merx); and Onkologische Schwerpunktpraxis, Weiden, Germany (J. Weiß).
Conflict of interest
Eva Lengfelder, Andreas Hochhaus, Andreas Reiter, Wolf-Karsten Hofmann, and Rüdiger Hehlmann are consultants or have advisory roles at Novartis Pharmaceuticals. Eva Lengfelder received research funding for this trial from Novartis Pharmaceuticals.
- 3.James C, Ugo V, Couédic J, Staerk J, Delhommeau F, Lacout C, Garçon L, Raslova H, Berger R, Bennaceur-Griscelli A, Villeval JL, Constantinescu SN, Casadevall N, Vainchenker W (2005) A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera. Nature 434:1144–1148PubMedCrossRefGoogle Scholar
- 4.Cross N (2011) Genetic and epigenetic complexity in myeloproliferative disorders. Hematology Am Soc Hematol Educ Program 2011:208–214Google Scholar
- 10.Löfvenberg E, Nordenson I, Wahlin A (1990) Cytogenetic abnormalities and leukemic transformation in hydroxyurea-treated patients with Philadelphia chromosome negative chronic myeloproliferative disorders. Cancer Genet Cytogenet 67:49–57Google Scholar
- 11.Barosi G, Birgegard G, Finazzi G, Griesshammer M, Harrison C, Hasselbalch H, Kiladijan JJ, Lengfelder E, Mesa R, Mc Mullin MF, Passamonti F, Reilly JT, Vannucchi AM, Barbui T (2010) A unified definition of clinical resistance and intolerance to hydroxycarbamide in polycythaemia vera and primary myelofibrosis: results of a European LeukemiaNet (ELN) consensus process. Br J Haematol 148:961–963PubMedCrossRefGoogle Scholar
- 21.Pierre R, Imbert M, Thiele J, Vardiman JW, Brunning RD, Flandrin G (2001) Polycthaemia vera. In: Jaffe ES, Harris NL, Stein H, Vardiman JW (eds) World Health Organization classification of tumors. Pathology and genetics. Tumors of haematopoietic and lymphoid tissues. IARC, Lyon, pp 32–34Google Scholar
- 22.Schoch C, Schnittger S, Bursch S, Gerstner D, Hochhaus A, Berger U, Hehlmann R, Hiddemann W, Haferlach T (2002) Comparison of chromosome banding analysis, interphase- and hypermetaphase-FISH, qualitative and quantitative PCR for diagnosis and for follow-up in chronic myeloid leukemia: a study on 350 cases. Leukemia 16:53–59PubMedCrossRefGoogle Scholar
- 23.Shaffer L, Slovak M, Campbell L (2009) ISCN 2009: an international system for human cytogenetic nomenclature. Karger, BaselGoogle Scholar